

## Firm Says New Ebola Rapid Testing Technologies Will Detect Surface and Airborne Infectious Viruses in Minutes

**By: Homeland Security Today Staff**

**10/23/2014 ( 6:21am)** — A new suite of mobile bio-detection technologies that can quickly detect the Ebola virus and other potentially lethal pathogens used in bioterrorism is in development by PathSensors Inc., a biotechnology and environmental testing company, but could be some time before its able to be fielded, industry sources told Homeland Security Today.

“Now that Ebola is a critical detection priority, we can deploy systems early next year, once we have a strategic partner in place to handle expanded production,” said PathSensors CEO Ted Olsen. “Containment starts with accurate and timely detection so the faster that you can achieve detection the quicker the population can be protected from these worldwide threats.”

The company said its mobile PathSensor systems will be easy-to-use, require minimal training and can detect infectious pathogens (virus, bacteria or toxin) from safely obtained samples. Portable PathSensors systems can be deployed for pathogen detection at any port of entry (air, land and water) as well as healthcare facilities and entertainment venues.

“Onsite personnel can handle testing easily and receive a result in less than five minutes, thereby eliminating hours of critical transportation to, and processing time at a lab facility,” the company said

“Government agencies suddenly are hard-pressed for rapid detection in point-of-entry systems for inadvertent or intentional bio threats,” said airport security expert Peter Harris, president of Yankee Foxtrot, Inc., a security management consulting firm and a PathSensors director. “PathSensors systems can be used as standalone technologies or integrated with other bio-detection technologies. Together, they can be used to test a patient as well as the seat, surfaces touched, and places visited by the infected party to ensure complete remediation.”

PathSensors CANARY technology licensed from the MIT-Lincoln Laboratory delivers extremely rapid detection of more than 25 pathogens at previously unattainable levels of speed and sensitivity. CANARY incorporates pathogen-specific antibodies expressed on a biosensor surface that, in the presence of a pathogen (virus, bacteria or toxin), trigger an intracellular calcium release that in-turn activates bioluminescent proteins to generate the emission of light.

PathSensors’ financial partners in developing the new mobile pathogenic detection technology include Blue Venture Investors, Empower Baltimore Management Corporation, Chesapeake Emerging Opportunities Club, and the Virginia Active Angel Network.